(S)-ROSCOVITINE

(S)-Roscovitine ((S)-Seliciclib; (S)-CYC202) is a potent and cross the blood-brain barrier CDKs inhibitor. (S)-Roscovitine shows neuroprotective efficacy. (S)-Roscovitine has the potential for the research of stroke[1][2].

CDK1: ≤1 μM (IC₅₀); CDK2: ≤1 μM (IC₅₀); CDK5: ≤1 μM (IC₅₀); CDK7: ≤1 μM (IC₅₀); CDK9: ≤1 μM (IC₅₀)

+4°C

[1] Le Roy L, et al. Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells. Cells. 2021 Jan 8;10(1):104. DOI:10.3390/cells10010104
[2] Menn B, et al. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010 Aug 12;5(8):e12117. DOI:10.1371/journal.pone.0012117